Announcements Trials
Browse Landscape

Phase

Phase 2 104Phase 1/2 52Phase 1 34Phase 3 13Phase NA 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 21Neoplasms 8Prostatic Neoplasms 7Glioblastoma 6Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Polycystic Ovary Syndrome 4Ovarian Neoplasms 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Skin Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Glioma 3Depression 3Colorectal Neoplasms 3Brain Neoplasms 3Thyroid Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroma, Acoustic 2Neurofibromatosis 2 2Myelodysplastic Syndromes 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Has results × Triple Negative Breast Neoplasms × Clear all
NCT03197389 2021-05-19

Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

Universitaire Ziekenhuizen KU Leuven

Phase EARLY_PHASE1 Completed
54 enrolled 9 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡